MYND Life Sciences Inc. (MYND.CN)
| Previous Close | 0.1100 |
| Open | 0.1200 |
| Bid | 0.1000 x N/A |
| Ask | 0.1100 x N/A |
| Day's Range | 0.1200 - 0.1200 |
| 52 Week Range | 0.0700 - 2.1500 |
| Volume | |
| Avg. Volume | 21,694 |
| Market Cap | 5.63M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0980 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
MYND Life Sciences Announces $3.5 Million Share Offering
Vancouver, British Columbia--(Newsfile Corp. - April 21, 2022) - MYND Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), is pleased to announce that it plans to undertake a non-brokered private placement offering (the "Offering") of common shares in share capital of the Company ("Shares") to raise gross proceeds of a minimum of $3,000,000 up to $3,500,000, or such other amounts as may be determined by the Company.The Offering will close immediately after (and ...
- Baystreet
Stocks in play: MYND Life Sciences
Announced it has entered into a non-binding memorandum of understanding to acquire all the issued and ...
- Newsfile
MYND Life Sciences Executes a Non-Binding MOU with Tidal Psychedelics
MYND expresses the intention to acquire all the issued and outstanding shares of Tidal Psychedelics Vancouver, British Columbia--(Newsfile Corp. - March 16, 2022) - MYND Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced it has entered into a non-binding memorandum of understanding ("MOU") to acquire all the issued
